Reference context 1
>= 125 nmol/L
- Population
- Adults
- Age range
- 18
- Specimen
- Serum / plasma
High Lp(a) risk-enhancing threshold
The 2026 ACC/AHA guideline treats Lp(a) >=125 nmol/L and above as a risk-enhancing level in cardiovascular assessment.
Information about a laboratory test
High Lp(a) is associated with atherosclerotic cardiovascular risk even when routine LDL appears acceptable.
Measures lipoprotein(a), an LDL-like particle with an attached apolipoprotein(a).
Used to refine inherited cardiovascular-risk assessment; the 2026 ACC/AHA guideline recommends measuring Lp(a) at least once in adulthood.
Lower Lp(a) generally corresponds to less Lp(a)-related additional risk.
High Lp(a) is associated with atherosclerotic cardiovascular risk even when routine LDL appears acceptable.
Use the laboratory report as context, but treatment goals and risk thresholds vary with age, cardiovascular risk, diabetes, kidney disease, and current therapy.
>= 125 nmol/L
High Lp(a) risk-enhancing threshold
The 2026 ACC/AHA guideline treats Lp(a) >=125 nmol/L and above as a risk-enhancing level in cardiovascular assessment.
Reference ranges may vary by laboratory, method used, age, sex, pregnancy status, and clinical context. The reference range on your own laboratory report takes precedence.
Lp(a) is largely genetically determined and relatively stable over life. A fixed conversion between mg/dL and nmol/L should not be assumed.
Lipoprotein (a) Blood Test — U.S. National Library of Medicine (MedlinePlus)
Government medical reference · 2026 · Lp(a) purpose, genetic stability and cardiovascular-risk context · Verified: Aug 12, 2026
2026 Guideline on the Management of Dyslipidemia – ACC/AHA release — American College of Cardiology / American Heart Association
Professional guideline summary · 2026 · Current dyslipidemia guidance; LDL/non-HDL goals, ApoB and Lp(a) risk assessment · Verified: Aug 12, 2026